Miles W. Griffis
-
Research updates, July 7
An autopsy study found persistent SARS-CoV-2 virus in the hearts of some people who had died after having COVID-19. A part of the National Institute of Health’s RECOVER program, the researchers shared their unpublished results in a poster at a pathology conference this spring.
-
Research updates, June 30
A recent imaging study in Sage Journals identified metabolic dysfunction in the brains of people with Long COVID who experience PEM. The study assessed 40 people with the disease from a Long COVID clinic with an advanced imaging technique that can detect various cancers and neurologic conditions.
-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say.
-
Research updates, June 23
A new study found that people with Long COVID were significantly more likely to experience cardiovascular disease after COVID-19. Published in Clinical Medicine Insights: Cardiology, researchers assessed a retrospective cohort of over 8,000 people who had a prior SARS-CoV-2 infection, discovering that Long COVID symptoms were associated with higher odds of cardiovascular disease, particularly angina…
-
Research updates, June 16
Two recent studies have added more evidence that the diabetes drug metformin can reduce the risk of Long COVID.
-
Research updates, June 9
A new study published in Alzheimer’s and Dementia found more evidence of alterations associated with Alzheimer’s disease in people with Long COVID. Notably, scientists identified a larger choroid plexus, a region of blood vessels in the brain, as well as reduced cerebral blood flow.
-
Research updates, June 2
The COVID-19 antiviral ensitrelvir (Xocova), was recently approved by the Food and Drug Administration. The oral drug was approved as PEP, or post-exposure prophylaxis, meaning it is taken within 72 hours after coming in contact with someone who has COVID-19.
-
Research updates, May 26
More research articles
-
Research updates, May 19
More research updates
-
Research updates, May 12
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance